Literature DB >> 23447724

Perampanel: Getting AMPed for AMPA Targets.

Joseph I Sirven.   

Abstract

Entities:  

Year:  2012        PMID： 23447724      PMCID： PMC3577133          DOI： 10.5698/1535-7511-12.6.241

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  5 in total

1.  Tolerability and safety of perampanel: two randomized dose-escalation studies.

Authors:  G L Krauss; M Bar; V Biton; J A Klapper; I Rektor; N Vaiciene-Magistris; D Squillacote; D Kumar
Journal:  Acta Neurol Scand       Date:  2011-08-29       Impact factor: 3.209

2.  Revisiting AMPA receptors as an antiepileptic drug target.

Authors:  Michael A Rogawski
Journal:  Epilepsy Curr       Date:  2011-03       Impact factor: 7.500

Review 3.  Pharmacotherapy of epilepsy: newly approved and developmental agents.

Authors:  Linda J Stephen; Martin J Brodie
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

4.  Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

Authors:  G L Krauss; J M Serratosa; V Villanueva; M Endziniene; Z Hong; J French; H Yang; D Squillacote; H B Edwards; J Zhu; A Laurenza
Journal:  Neurology       Date:  2012-04-18       Impact factor: 9.910

5.  Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.

Authors:  Jacqueline A French; Gregory L Krauss; Victor Biton; David Squillacote; Haichen Yang; Antonio Laurenza; Dinesh Kumar; Michael A Rogawski
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.